Clinical Trials Browser

Phase 1 × tomivosertib × Other hematologic neoplasm × Clear all

NCT05744739 2025-10-21

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute